Surfing the MASH Tsunami
Driving the Discussion in Fatty Liver Disease. Join hepatology researcher and Key Opinion Leader Jörn Schattenberg, Liver Wellness Advocate Louise Campbell, and Forecasting and Pricing Guru Roger Green and a global group of Key Opinion Leaders and patient advocates as they discuss key issues in Fatty Liver disease, including epidemiology, drug development, clinical pathways, non-invasive testing, health economics and regulatory issues, from their own unique perspectives on the Surfing the MASH Tsunami podcast. #MASH #MAFLD #FattyLiver #livertwitter #AASLD #GlobalLiver #NoNASH #EASL
- Update frequency
- every day
- Average duration
- 26 minutes
- Episodes
- 1069
- Years Active
- 2020 - 2025
S2 E5.2 — After the FDA Webcast: Discussing Clinical Endpoints
The Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale discuss sections of the FDA Webcast that centered on clinical and surr…
S2 E5.1 - After the FDA Webcast: Beginning and Ending Perceptions
The Surfers and guests Manal Abdelmalek, Naim Alkhouri and Akero Therapeutics Chief Development Officer Kitty Yale share high-level perspectives on the FDA Webcast, both before and afte…
S2 E4.2 - Anticipating The FDA Webcast: Specific Items to Listen For
Manal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development.
In this conversation, Professor Manal Abdelmalek joins …
S2 E4.1 - Anticipating the FDA Webcast: Overall Areas for Guidance
Manal Abdelmalek joins the Surfers to discuss key themes they hope to hear at the January 29 FDA Webcast on NASH Drug Development.
In this conversation, Professor Manal Abdelmalek joins …
S2 E5 - What We Learned at Today's FDA Webcast on NASH Drug Development
Manal Abdelmalek, Naim Alkhouri, and Akero Therapeutics Chief Development Officer Kitty Yale join the Surfers to discuss Friday's FDA webcast on NASH Drug Development.
Friday's FDA Webca…
S2 E4 - What to Listen For Friday at the FDA Webcast
Manal Abdelmalek joins the Surfers to share expectations in advance of Friday's FDA Webcast on NASH Drug Development.
FDA's Friday webcast titled "Regulatory Perspectives for Development…
S2 E3.2 - Call to action: Can We use COVID-19 Vaccine Centers to support Liver health?
The Surfers discuss ways that COVID-19 Vaccine Centers might present an opportunity to educate and screen patients on Liver Health
Stephen Harrison suggests that COVID-19 Vaccine Centers…
S2 E3.1 - Challenges Disadvantaged Minorities Face in Liver Health
Donna Cryer and Louise Campbell discuss how governmental action (or inaction) couple with community efforts to shape Liver Health initiatives in the US, UK, and Australia.
The Surfers di…
S2 E3 A Call to Action on MLK Day: Supporting disadvantaged Minorities in Managing Liver Health
Donna Cryer joins the Surfers to explore efforts to support residents in disadvantaged minority communities in the US, UK, and Australia in improving their Liver Health and awareness.
"T…
S2 E2.3 - Partners and enablers Necessary to Help Drive Broader NAFLD and Non-Communicable Disease
The Surfers end this episode by discussing the need for public education to create the awareness necessary for change.
This conversation covers a broad range of topics -- public health n…
S2 E2.2 - Economic and Patient Motivation Costs and Value of telemedicine and New Non-Invasive Diagnostic Testing
Evaluating the economic and patient-motivating value of enhanced telemedicine and mobile non-invasive testing technologies in improving NAFLD diagnosis and lowering rates of non-communi…
S2 E2.1 - Innovations in Telemedicine and Mobile Technology can improve care for NAFLD patients
Innovations in Telemedicine and Mobile Technologies are already changing patient care in ways that will remain and expand in the "New Normal" after the COVID-19 pandemic is less urgent.
…
S2 E2 — How COVID-19 is changing patient management and clinical trials
Manal Abdelmalek joins the Surfers to describe long-term changes in patient management that improved diagnostic and telecommunication technologies can drive in response to new COVID-19 …
S2 E1.3 - Challenges and Big Ideas for NAFLD/NASH Patient Diagnosis and Treatment in the Post-Second Wave World
Question: If NALFD patients have poorer COVID-19 prognoses, how can we use this fact to drive broader population-based screening?
This conversation asks a two-part question: How do we mo…
S2 E1.2 Successfully Managing Clinical Trials during COVID-19's Second Wave
The COVID-19 conversation continues with the group focusing on challenges in clinical trial execution and how innovative logistics and consistent education can lessen or overcome them.
I…
S2 E1.1 - How Recent COVID-19 News Affects NAFLD and NASH Patients
Manal Abdelmalek joins the Surfers to consider the three most important COVID-19 stories today.
The conversation focuses on the British variant, the new vaccines, and the physical and em…
S2 E1 - How Will COVID-19 Affect the Fatty Liver Community in 2021?
Manal Abdelmalek joins the Surfers to discuss how recent COVID-19 news might affect Fatty Liver patients and what the medical profession and BioPharma companies can do to support patien…
44.4 2020 Year In Review: How Patients and Patient Advocates reacted to a year of lows and high
Wayne Eskridge describes how hope fell and then rose as patients did not receive the drug approval they expected but then learned about exciting paths for new agents and non-invasive te…
44.3 2020 Year In Review: Revisiting the "MAFLD vs. NAFLD" debate
Louise Campbell questions the implication of APASL and ALEH endorsing "MAFLD" as Fatty Liver Disease nomenclature and Stephen Harrison discusses behind-the-scenes activities to resolve …
44.2 2020 Year In Review: Fatty Liver Disease Enters the Public Dialogue in Germany
Joern Schattenberg discusses the public health implications of German newspapers beginning to discuss Fatty Liver Disease
For Joern Schattenberg, reading about Non-Alcoholic Fatty Liver …